Research finds insufficient data transparency for FDA-cleared AI devices in Alzheimer’s imaging, raising bias and generalizability concerns.
Key Details
- 124 AI/ML-based devices for Alzheimer's disease and related dementias (ADRD) were FDA-authorized between January 2015 and December 2024.
- 291.7% (22/24) were cleared via the 510(k) pathway; 8.3% (2/24) through de novo classification.
- 3For 12 devices, there was no info on training or validation data in FDA summaries or peer-reviewed articles.
- 4Only 2 FDA summaries (8.3%) included external validation data; 10 peer-reviewed articles (41.7%) provided such data.
- 5Reporting of disease status, age, sex, race, and ethnicity was rare across most devices; demographic transparency was lacking.
- 6Most devices (21) were reviewed by radiology panels and primarily involved MRI and PET imaging.
Why It Matters
Transparent disclosure of training and validation data, especially demographic details, is vital for assessing bias and clinical accuracy in AI-based imaging devices. Without sufficient data transparency, there is uncertainty about the generalizability and safety of these AI tools in real-world, diverse patient populations.
Source
AuntMinnie
Related News
•Radiology Business
Real-World Study: Radiology AI Best in Emergency and Inpatient Settings
A commercial AI tool for intracranial aneurysm detection outperformed in inpatient and emergency settings but yielded limited benefits for outpatients in a major health system study.
•Radiology Business
New Rubric Enhances Safety of AI-Generated Radiology Summaries
Researchers developed a five-factor rubric to assess the safety and quality of AI-generated, patient-friendly radiology report summaries.
•Radiology Business
AI Model Surpasses Radiologists in Detecting Subtle Hip Fractures
A new AI model outperformed radiologists in identifying difficult-to-detect femoral neck fractures on radiographs.